Brief: Sellas Life Sciences Says Full Topline Phase 2 Data In Acute Myeloid Leukemia And FDA Regulatory Review Expected In 1H 2025 For SLS009
08/01/2025 14:15
Jan 8 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES GROUP INC: FULL TOPLINE PHASE 2 DATA
IN
ACUTE MYELOID LEUKEMIA AND FDA REGULATORY REVIEW EXPECTED IN 1H
2025 FOR SLS009
Source text: urn:newsml:reuters.com:*:nGNX5Jl5cR
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses